Pub. Date : 2007 Jul 15
PMID : 17634558
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. | Sorafenib | cyclin dependent kinase inhibitor 1A | Homo sapiens |
| 2 | Sorafenib also blocked vorinostat-mediated induction of p21(CIP1). | Sorafenib | cyclin dependent kinase inhibitor 1A | Homo sapiens |
| 3 | Sorafenib also blocked vorinostat-mediated induction of p21(CIP1). | Sorafenib | cyclin dependent kinase inhibitor 1A | Homo sapiens |
| 4 | Enforced expression of p21(CIP1) and particularly Mcl-1 significantly attenuated vorinostat/sorafenib-mediated lethality. | Sorafenib | cyclin dependent kinase inhibitor 1A | Homo sapiens |
| 5 | Enforced expression of p21(CIP1) and particularly Mcl-1 significantly attenuated vorinostat/sorafenib-mediated lethality. | Sorafenib | cyclin dependent kinase inhibitor 1A | Homo sapiens |
| 6 | CONCLUSIONS: These findings suggest that combined treatment with vorinostat and sorafenib synergistically induces apoptosis in CML cells through a process that involves Mcl-1 down-regulation and inhibition of p21(CIP1) induction. | Sorafenib | cyclin dependent kinase inhibitor 1A | Homo sapiens |
| 7 | CONCLUSIONS: These findings suggest that combined treatment with vorinostat and sorafenib synergistically induces apoptosis in CML cells through a process that involves Mcl-1 down-regulation and inhibition of p21(CIP1) induction. | Sorafenib | cyclin dependent kinase inhibitor 1A | Homo sapiens |